Leerink analyst David Larsen believes the recent pullback in shares of Diplomat Pharmacy (DPLO) provides a "compelling" entry point into the name. True specialty pharmacies like Diplomat have "sound business models" and remain well positioned to deliver 30%-plus annual growth over the next several years, Larsen tells investors in a research note. The analyst does not believe the company is at risk of being excluded from the pharmacy networks of the large pharmacy benefit managers Express Scripts (ESRX), CVS Health (CVS) and Optum. He keeps an Outperform rating on Diplomat.